Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Products under Development by Stage of Development | 8 | 1 |
| Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Products under Development by Therapy Area | 9 | 1 |
| Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Products under Development by Indication | 10 | 1 |
| Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Unknown Stage Products | 13 | 1 |
| Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Products under Development by Companies | 14 | 2 |
| Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Products under Development by Universities/Institutes | 16 | 2 |
| Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Therapeutics Assessment | 18 | 4 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 1 |
| Assessment by Molecule Type | 21 | 1 |
| Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Companies Involved in Therapeutics Development | 22 | 5 |
| 1st Order Pharmaceuticals Inc | 22 | 1 |
| Grunenthal GmbH | 23 | 1 |
| Saniona AB | 24 | 1 |
| SciFluor Life Sciences, LLC | 25 | 1 |
| Valeant Pharmaceuticals International, Inc. | 26 | 1 |
| Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Drug Profiles | 27 | 10 |
| 1OP-2198 Drug Profile | 27 | 1 |
| ezogabine Drug Profile | 28 | 3 |
| NH-34 Drug Profile | 31 | 1 |
| SF-0034 Drug Profile | 32 | 2 |
| Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain Drug Profile | 34 | 1 |
| Small Molecules to Activate KCNQ and TSPO for Pain Drug Profile | 35 | 1 |
| Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder Drug Profile | 36 | 1 |
| Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Discontinued Products | 37 | 1 |
| Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Featured News &Press Releases | 38 | 10 |
| Jun 19, 2015: SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience | 38 | 1 |
| Apr 16, 2015: The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Clinical Research Institute Collaborate with GlaxoSmithKline on New ALS Clinical Trial | 39 | 1 |
| Feb 04, 2015: Anti-epilepsy drug preserves brain function after stroke | 39 | 1 |
| Jan 08, 2015: SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related Neurological Disorders | 40 | 1 |
| Jun 25, 2013: SciFluor Life Sciences Presents New Preclinical Data For SF0034 At 30th International Epilepsy Congress | 41 | 1 |
| May 31, 2013: EMA's CHMP Recommends Restricting Trobalt To Last-line Therapy In Partial Epilepsy | 42 | 1 |
| May 27, 2013: Valeant Pharma's Retigabine Shows Promise In Preventing Noise-induced Tinnitus In Animal Model, Pitt Researchers Report | 43 | 1 |
| Jul 27, 2011: Glaxosmithkline's Drug Retigabine Added To NHS Treatment Options | 44 | 1 |
| Jun 16, 2011: Retigabine May Further Help People With Epilepsy, NICE Says | 44 | 1 |
| Jun 13, 2011: Valeant And GlaxoSmithKline Announce FDA Approval For Potiga | 45 | 1 |
| Apr 18, 2011: GSK And Valeant Respond To FDA On Ezogabine | 46 | 1 |
| Mar 29, 2011: GSK And Valeant Receive European Authorization For Trobalt | 46 | 1 |
| Jan 21, 2011: GSK And Valeant Receive Positive Opinion In Europe From CHMP For Trobalt | 47 | 1 |
| Dec 01, 2010: GSK And Valeant Receive FDA Complete Response Letter For Ezogabine | 47 | 1 |
| Aug 30, 2010: GSK And Valeant Receive New FDA PDUFA Goal Date For Ezogabine | 47 | 1 |
| Appendix | 48 | 2 |
| Methodology | 48 | 1 |
| Coverage | 48 | 1 |
| Secondary Research | 48 | 1 |
| Primary Research | 48 | 1 |
| Expert Panel Validation | 48 | 1 |
| Contact Us | 48 | 1 |
| Disclaimer | 49 | 1 |
